Merck gets a patent win for muscle relaxant reversal drug
Merck won a patent lawsuit that allows it to keep marketing a blockbuster surgery drug until early 2026.
The pharma company said Tuesday that the US District Court for the District of New Jersey ruled in its favor, saying Merck had correctly calculated the period of a Patent Term Extension, a regulatory tool that can be used to restore some patent time lost during regulatory review of a new drug.
“We look forward to continuing to provide Bridion to patients who need it,” a Merck spokesperson said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.